nach oben

Current Diabetes Reports

Erschienen in:

01.06.2012 | Management of Macrovascular Disease in Diabetes (S Inzucchi and R Goldberg, Section Editors)

Update on Diabetic Cardiomyopathy: Inches Forward, Miles to Go

verfasst von: Maggie N. Tillquist, Thomas M. Maddox

Erschienen in: Current Diabetes Reports | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Diabetes causes cardiomyopathy, both directly and by potentiating the effect of its common comorbidities, coronary artery disease and hypertension, on its development. With the common and growing prevalence of diabetes worldwide, diabetic cardiomyopathy is a significant public health problem. Recent research identifies both mitochondrial dysfunction and epigenetic effects as newly recognized factors in the complex pathogenesis of diabetic cardiomyopathy. Diagnostically, specialized echocardiography techniques, cardiac magnetic resonance imaging, and serologic biomarkers all appear to have promise in detecting the early stages of diabetic cardiomyopathy. Research into treatments includes both traditional diabetes and heart failure therapies, but also explores the potential of newer metabolic and anti-inflammatory agents. These recent insights provide important additions to our knowledge about diabetic cardiomyopathy, but much remains unknown.

Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595–602.PubMedCrossRef

Aneja A, Tang W, Bansilal S, et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008;121(9):748–57.PubMedCrossRef

Masoudi FA, Inzucchi SE. Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol. 2007;99(4):113–32.CrossRef

Battiprolu P, Gillette T, Wang Z, Lavandero S, Hill J. Diabetic cardiomyopathy: mechanisms and therapeutic targets. Drug Discov Today Dis Mech. 2010;7(2):e135–43.PubMedCrossRef

Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25(4):543–67.PubMedCrossRef

Sasso FC, Rambaldi PF, Carbonara O, et al. Perspectives of nuclear diagnostic imaging in diabetic cardiomyopathy. Nutr Metab Cardiovasc Dis. 2010;20(3):208–16.PubMedCrossRef

Murarka S, Movahed MR. Diabetic cardiomyopathy. J Card Fail. 2010;16(12):971–9.PubMedCrossRef

Van Buren P, LeWinter M. Heart failure: a companion to Braunwald’s heart disease. Chapter 26—heart failure as a consequence of diabetic cardiomyopathy. Elsevier Inc. 2011. pp. 408–418.

Shindler DM, Kostis JB, Yusuf S, et al. Diabetes Mellitus, a predictor of morbidity and mortality in the studies of the left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996;77:1017–20.PubMedCrossRef

10.

Ryden L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J. 2000;21:1967–78.PubMedCrossRef

11.

National Diabetes Information Clearinghouse. Available at http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#Diagnosed20. Accessed December 2011.

12.

•• Maisch B, Alter P, Pankuweit S. Diabetic cardiomyopathy – fact or fiction? Herz. 2011;36(2):102–15. This review provided a new, expanded classification of diabetic cardiomyopathy stages..PubMedCrossRef

13.

•• Singh G, Sharma R, Khullar M. Epigenetics and diabetic cardiomyopathy. Diabetes Res Clin Pract. 2011;94(1):14–21. This review outlined the role of epigenetic phenomena in diabetic cardiomyopathy.PubMedCrossRef

14.

Voulgari C, Papadoglannis D, Tentolouris N. Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag. 2010;6:883–903.PubMedCrossRef

15.

Mytas DZ, Stougiannos PN, Zairis MN, et al. Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options. J Diabetes Complications. 2009;23(4):273–82.PubMedCrossRef

16.

Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF. The diabetic cardiomyopathy. Acta Diabetol. 2011;48(3):173–81.PubMedCrossRef

17.

Wenmeng W, Qizhu T. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy. Med Hypotheses. 2011;76(2):181–3.PubMedCrossRef

18.

Rollm N, Ingul C, Hansen H, et al. Increased sensitivity to ischemia in an early diabetic cardiomyopathy: the role of calcium handling. Biophys J. 2009;96(3):119a.CrossRef

19.

Falcao-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progression diagnosis and treatment. Heart Fail Rev. 2011; [Epub ahead of print].

20.

Flotats A, Carrio I. Is cardiac autonomic neuropathy the basis of non-ischemic diabetic cardiomyopathy? JACC: Cardiovasc Imag. 2010;3(12):1216–7.CrossRef

21.

Mustonen J, Mantysaari M, Kuikka J. Decreased myocardial 123I-metaiodobenzylguanidine uptake is associated with disturbed LV diastolic filling in diabetes. Am Heart J. 1992;123:804–5.PubMedCrossRef

22.

Bisognano JD, Weinberger HD, Bohimeyer TJ, et al. Myocardial-directed overexpression of the human B(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000;32:817–30.PubMedCrossRef

23.

•• Duncan JG. Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta Mol Cell Res. 2011;1813(7):1351–9. This review outlined the role of mitochondrial dysfunction in the pathophysiology of diabetic cardiomyopathy.CrossRef

24.

Berg TJ, Snorgaard O, Faber J, et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care. 1999;22:118–1190.CrossRef

25.

Kajstura J, Fiordaliso F, Androli AM, et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-medicated oxidative stress. Diabetes. 2001;50:1414–24.PubMedCrossRef

26.

•• From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and preclinical diastolic dysfunction: a population-based study. JACC. 2010;55(4):300–5. This study investigated characteristics of diabetic patients with diastolic dysfunction from 2001–2007. It provides an original detailed analysis of subclinical diastolic dysfunction in this population.PubMed

27.

Maya L, Villarreal F. Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. J Mol Cell Cardiol. 2010;48(3):524–9.PubMedCrossRef

28.

Fang ZY, Schull-Meade R, Downey M, et al. Determinants of subclinical diabetic heart disease. Diabetologia. 2005;48:394–402.PubMedCrossRef

29.

•• Ernande L, Bergerot C, Rietzchel E, et al. Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr. 2011;24(11):1268–75. This paper challenged the previously held hypothesis that diastolic dysfunction is the first marker of diabetic cardiomyopathy, and argued that systolic strain alteration may precede diastolic dysfunction.PubMedCrossRef

30.

Ng AC, Delgado V, Bertini M, et al. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol. 2009;104:1398–401.PubMedCrossRef

31.

Nakai H, Takeuchi M, Nishikage T, et al. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration. Eur J Echocardiogr. 2009;10:926–32.PubMedCrossRef

32.

Boyer JK, Thanigaraj S, Schechtman KB, Perez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive diabetic mellitus. Am J Cardiol. 2004;93:870–5.PubMedCrossRef

33.

Di Bonito P, Moio N, Cavuto L, et al. Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabet Med. 2005;22:1720–5.PubMedCrossRef

34.

Kim DH, Kim YJ, Kim HK, et al. Usefulness of mitral annulus velocity for the early detection of left ventricular dysfunction in a rat model of diabetic cardiomyopathy. J Cardiovasc Ultrasound. 2010;18(1):6–11.PubMedCrossRef

35.

Thrainsdottir I, Maimberg K, Olsson A, et al. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res. 2004;1:40–3.PubMedCrossRef

36.

Rosen R, Rump AF, Rosen P. The ACE-inhibitor captopril improves myocardial perfusion in spontaneously diabetic (BB) rats. Diabetologia. 1995;38:509–17.PubMedCrossRef

37.

Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, Lammertsma AA, Smit JW, Diamant M. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009;54(16):1524–32.

38.

Epshteyn V, Morrison K, Krishnaswamy P, et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care. 2003;26:2081–7.PubMedCrossRef

39.

Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1–e90.

40.

•• Romano S, Mauro M, Fratini S, et al. Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides. Cardiovasc Diabetol. 2010;9:89. This study established BNP as a screening tool for subclinical diabetic cardiomyopathy.PubMedCrossRef

41.

Mogelvang R, Goetze JP, Pedersen SA, et al. Preclinical systolic and diastolic dysfunction assessed by tissue Doppler imaging is associated with elevated plasma pro-B-type natriuretic peptide concentrations. J Card Fail. 2009;15:489–95.PubMedCrossRef

42.

Betti I, Castelli G, Barchielli A, et al. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. J Card Fail. 2009;15:377–84.PubMedCrossRef

43.

Ihm S, et al. Serum carboxy-terminal propeptide of type 1 procollagen (PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus. Int J Cardiol 2007;e36–8.

44.

Martos R, Baugh J, Ledwidge M, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115:888–95.PubMedCrossRef

45.

Meier M, Hummel M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc Health Risk Manag. 2009;5:859–71.PubMedCrossRef

46.

Von Bibra H, Hansen A, Dounis V, et al. Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Hear Vessel. 1994;9:121–8.CrossRef

47.

Von Bibra H, Siegmund T, Hansen A, et al. Augmentation of myocardial function by improved glycemic control in patients with type 2 diabetes mellitus. Dtsch Med Wochenschr. 2007;132:729–34.CrossRef

48.

Bibra H, Siegmund T, Ceriello A, et al. Optimized postprandial glucose control is associated with improved cardiac/vascular function—comparison of three insulin regimens in well-controlled type 2 diabetes. Horm Metab Res. 2009;41(2):109–15.PubMedCrossRef

49.

•• Hordern MD, Coombes JS, Cooney LM, et al. Effects of exercise intervention on myocardial function in type 2 diabetes. Heart. 2009;95(16):1343–9. This study failed to find an effect of exercise on diastolic dysfunction in diabetic patients.PubMedCrossRef

50.

Naka KK, Pappas K, Papathanassiuo K, et al. Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue Doppler imaging study. Cardiovasc Diabetol. 2010;23:9–57.

51.

Hare JL, Horder MD, Leano R, et al. Application of an exercise intervention on the evolution of diastolic dysfunction in patients with diabetes mellitus: efficacy and effectiveness. Circ Heart Fail. 2011;4(4):441–9.PubMedCrossRef

52.

•• ADVANCE Echocardiography Substudy Investigators, ADVANCE Collaborative Group. Effects of perinopril-indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE Echocardiography Substudy. J Hypertens. 2011;29(7):1439–47. This study failed to find an effect of a combination ACEI/diuretic on diastolic dysfunction among diabetic patients.

53.

Rajesh M, Mukhopadyay P, Batkai S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol. 2010;56(25):2115–25.PubMedCrossRef

Titel: Update on Diabetic Cardiomyopathy: Inches Forward, Miles to Go
verfasst von: Maggie N. Tillquist
Thomas M. Maddox
Publikationsdatum: 01.06.2012
Verlag: Current Science Inc.
Erschienen in: Current Diabetes Reports / Ausgabe 3/2012
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-012-0274-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Glycemic Control and Cardiovascular Disease: What’s a Doctor to Do?

Diagnosis of Coronary Artery Disease in Persons with Diabetes Mellitus

Metformin Use Among Individuals at Risk for Type 2 Diabetes

Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus

Evidence-Based Medicine and the Selection of Lipid-Lowering Therapy in Type 2 Diabetes